JPWO2020112815A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020112815A5 JPWO2020112815A5 JP2021510452A JP2021510452A JPWO2020112815A5 JP WO2020112815 A5 JPWO2020112815 A5 JP WO2020112815A5 JP 2021510452 A JP2021510452 A JP 2021510452A JP 2021510452 A JP2021510452 A JP 2021510452A JP WO2020112815 A5 JPWO2020112815 A5 JP WO2020112815A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- population
- cells
- seq
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862771653P | 2018-11-27 | 2018-11-27 | |
| US62/771,653 | 2018-11-27 | ||
| PCT/US2019/063310 WO2020112815A1 (en) | 2018-11-27 | 2019-11-26 | Anti-lmp2 tcr-t cell therapy for the treatment of ebv-associated cancers |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022512538A JP2022512538A (ja) | 2022-02-07 |
| JPWO2020112815A5 true JPWO2020112815A5 (https=) | 2022-12-05 |
| JP2022512538A5 JP2022512538A5 (https=) | 2022-12-05 |
Family
ID=70854398
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021510452A Pending JP2022512538A (ja) | 2018-11-27 | 2019-11-26 | Ｅｂｖ関連がんの処置のための抗ｌｍｐ２ ｔｃｒ－ｔ細胞療法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US12139523B2 (https=) |
| JP (1) | JP2022512538A (https=) |
| KR (1) | KR20210098940A (https=) |
| CN (1) | CN113166224A (https=) |
| SG (1) | SG11202101671PA (https=) |
| TW (1) | TW202039540A (https=) |
| WO (1) | WO2020112815A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113621070A (zh) | 2020-05-06 | 2021-11-09 | 华夏英泰（北京）生物技术有限公司 | 一种t细胞抗原受体、其多聚体复合物及其制备方法和应用 |
| WO2021243695A1 (en) * | 2020-06-05 | 2021-12-09 | Guangdong Tcrcure Biopharma Technology Co., Ltd. | Tcr-t cell therapy targeting epstein-barr virus |
| CN112940108B (zh) * | 2021-03-19 | 2022-10-14 | 河南省肿瘤医院 | 识别ebv抗原的t细胞受体以及该t细胞受体的应用 |
| WO2023092452A1 (zh) * | 2021-11-26 | 2023-06-01 | 上海吉倍生物技术有限公司 | 识别ebv lmp2抗原的t细胞受体及其应用 |
| WO2025059162A1 (en) | 2023-09-11 | 2025-03-20 | Dana-Farber Cancer Institute, Inc. | Car-engager containing il-2 variants to enhance the functionality of car t cells |
| CN119390814B (zh) * | 2023-10-26 | 2025-06-27 | 上海市第一人民医院 | 一种t细胞受体及其制备方法和用途 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0917090D0 (en) * | 2009-09-29 | 2009-11-11 | Ucl Biomedica Plc | T-cell receptor |
| US8834889B2 (en) * | 2011-08-29 | 2014-09-16 | National Tsing Hua University | Antigen presenting composition and use thereof |
| GB201314404D0 (en) | 2013-08-12 | 2013-09-25 | Immunocore Ltd | T Cell Receptors |
| WO2016095783A1 (zh) | 2014-12-17 | 2016-06-23 | 中国科学院广州生物医药与健康研究院 | 识别eb病毒短肽的t细胞受体 |
| EP3331913A1 (en) | 2015-08-07 | 2018-06-13 | Novartis AG | Treatment of cancer using chimeric cd3 receptor proteins |
| GB201520191D0 (en) * | 2015-11-16 | 2015-12-30 | Cancer Rec Tech Ltd | T-cell receptor and uses thereof |
| GB201522592D0 (en) * | 2015-12-22 | 2016-02-03 | Immunocore Ltd | T cell receptors |
| CN106632659A (zh) * | 2016-08-05 | 2017-05-10 | 武汉赛云博生物科技有限公司 | 一种eb病毒特异性tcr及其重组慢病毒载体与应用 |
| CN110139873A (zh) * | 2016-10-03 | 2019-08-16 | 朱诺治疗学股份有限公司 | Hpv特异性结合分子 |
| CN110582509A (zh) * | 2017-01-31 | 2019-12-17 | 诺华股份有限公司 | 使用具有多特异性的嵌合t细胞受体蛋白治疗癌症 |
-
2019
- 2019-11-26 US US17/276,553 patent/US12139523B2/en active Active
- 2019-11-26 SG SG11202101671PA patent/SG11202101671PA/en unknown
- 2019-11-26 JP JP2021510452A patent/JP2022512538A/ja active Pending
- 2019-11-26 CN CN201980056915.5A patent/CN113166224A/zh active Pending
- 2019-11-26 KR KR1020217005780A patent/KR20210098940A/ko not_active Ceased
- 2019-11-26 WO PCT/US2019/063310 patent/WO2020112815A1/en not_active Ceased
- 2019-11-27 TW TW108143260A patent/TW202039540A/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI710572B (zh) | 改善配對的ｔ細胞受體 | |
| ES2816450T3 (es) | Uso de CAR basados en ICOS para mejorar la actividad antitumoral y la persistencia del CAR | |
| JP7198670B2 (ja) | 免疫調整性ｉｌ２ｒ融合タンパク質およびその使用 | |
| Rommelfanger et al. | Systemic combination virotherapy for melanoma with tumor antigen-expressing vesicular stomatitis virus and adoptive T-cell transfer | |
| EP3517125B1 (en) | Chimeric antigen receptor for efficient targeted proliferation in vitro and uses thereof | |
| SG11202111973RA (en) | Engineered t cells | |
| CN111051502A (zh) | 通用型嵌合抗原受体t细胞制备技术 | |
| MX2014003176A (es) | Celulas t diseñadas mediante arn para el tratamiento de cancer. | |
| CN111511911A (zh) | 表达特异性地识别人间皮素的细胞表面分子、il-7和ccl19的免疫活性细胞 | |
| CN107936120A (zh) | Cd19靶向性的嵌合抗原受体及其制法和应用 | |
| CN117545766A (zh) | 靶向ras突变的t细胞受体及其用途 | |
| KR20210090220A (ko) | 키메라 항원 수용체 기억-유사 (carml) nk 세포 및 이를 만들고, 이용하는 방법 | |
| CN113330038A (zh) | Cd20组合靶向的工程化免疫细胞 | |
| CN110564767A (zh) | 一种减毒病毒载体系统及其在制备抗恶性肿瘤的药物中的应用及药物使用方法 | |
| JPH10511542A (ja) | 標的化ｔリンパ球 | |
| CN110054698A (zh) | 抗cd19抗体的新型cd19-car载体的构建及应用 | |
| JPWO2020112815A5 (https=) | ||
| CN109554349B (zh) | Pd-1基因表达沉默的工程化免疫细胞 | |
| WO2023051361A1 (zh) | 工程化免疫细胞及其用途 | |
| TW202003049A (zh) | 結合至階段特異性胚胎抗原4 (ssea4)之嵌合抗原受體及其用途 | |
| CN111499766B (zh) | 针对慢性淋巴细胞白血病的免疫效应细胞、其制备方法和应用 | |
| US20210332381A1 (en) | Ligand Matched Transcription Control, Control Devices, and Solute Carriers | |
| JP2026506591A (ja) | 天然タンパク質ｔｓｈを抗原結合部位とした、ｔｓｈｒを標的とするｃａｒ－ｔ細胞の構築 | |
| WO2023093888A1 (zh) | 基于efna1构建的嵌合抗原受体免疫细胞制备及其应用 | |
| Whartenby et al. | Gene-modified cells for the treatment of cancer |